Kolexia
Farnault Laure
Hématologie
Hôpital La Conception
Marseille, France
131 Activités
198 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Lymphomes Tumeurs hématologiques Leucémie myéloïde Myélome multiple Sepsie COVID-19 Hypertension artérielle

Industries

A+A
74 collaboration(s)
Dernière en 2023
IQVIA
40 collaboration(s)
Dernière en 2023
Novartis
35 collaboration(s)
Dernière en 2023
Abbvie
9 collaboration(s)
Dernière en 2023

Dernières activités

Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88 and CXCR4 mutations and underlying haemopathy.
Journal of neurology   18 novembre 2023
CIDP IS PART OF THE SPECTRUM OF VEXAS SYNDROME, THERAPEUTIC IMPLICATIONS
2023 PNS Annual Meeting – Copenhagen, 17‐20 June 2023   09 octobre 2023
Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
British journal of haematology   10 septembre 2023
Impact of Next-Generation Sequencing in Diagnosis, Prognosis and Therapeutic Management of Acute Myeloid Leukemia/Myelodysplastic Neoplasms.
Cancers   22 juin 2023
Therapy-related myeloid neoplasms after 177Lu-DOTATATE therapy for metastatic neuroendocrine neoplasia: CPX-351 consolidated by allogeneic stem cells transplantation as applicable therapeutic strategy.
Leukemia & lymphoma   12 avril 2023
Determination of 5-azacitidine in human plasma by LC-MS/MS: application to pharmacokinetics pilot study in MDS/AML patients.
Cancer chemotherapy and pharmacology   01 mars 2023
Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of -Negative Myeloproliferative Neoplasm.
Cells   27 décembre 2022
Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study
Annual Meeting Abstracts 2022   15 novembre 2022
Azacitidine, a therapeutic option in Lewis and Sumner syndrome associated with VEXAS syndrome.
Revue neurologique   08 novembre 2022
Successful treatment with adapted high dose methotrexate in a hemodialysis patient with primary central nervous system lymphoma: 100mg/m seems sufficient.
Nefrologia   28 septembre 2022